7.91
Scisparc Ltd stock is traded at $7.91, with a volume of 29,399.
It is down -9.81% in the last 24 hours and up +116.12% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$8.77
Open:
$8.65
24h Volume:
29,399
Relative Volume:
0.08
Market Cap:
$4.47M
Revenue:
$927.00K
Net Income/Loss:
$-13.21M
P/E Ratio:
-0.0375
EPS:
-210.8843
Net Cash Flow:
$-4.77M
1W Performance:
+18.24%
1M Performance:
+116.12%
6M Performance:
-72.96%
1Y Performance:
+213.89%
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
SPRC
Scisparc Ltd
|
7.91 | 4.47M | 927.00K | -13.21M | -4.77M | -210.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Scisparc Ltd Stock (SPRC) Latest News
Neurothera Labs Announces Continuance into Ontario - TheNewswire
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
SciSparc (NASDAQ: SPRC) 20-F shows widening losses and going concern risk - Stock Titan
SPRC Stock Price, Quote & Chart | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
SciSparc stock rallies after AutoMax files motion on pending merger - MSN
SPRC Technical Analysis | Trend, Signals & Chart Patterns | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
Neurothera Labs Engages bullVestor for Investor Relations Activities - TheNewswire
SciSparc receives Nasdaq notice over stockholders’ equity shortfall - MSN
SPRC Stock Pops On Volatile Run As Traders Circle - timothysykes.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
SciSparc (SPRC) Stock Volume Ratio (Slips) 2026-04-20RSI Overbought Stocks - Cổng thông tin điện tử tỉnh Lào Cai
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
SPRC | SciSparc Ltd. Ordinary Shares Insider Trading - Quiver Quantitative
Amnon Ben Shay Net Worth (2026) - GuruFocus
Adi Zuloff Shani Net Worth (2026) - GuruFocus
Lior Vider Net Worth (2026) - GuruFocus
Is SciSparc (SPRC) Stock better than industry peers | Price at $3.02, Down 3.95%Open Stock Signal Network - UBND thành phố Hải Phòng
Block Trades: Can SciSparc Ltd scale operations efficientlyQuarterly Portfolio Summary & Breakout Confirmation Alerts - baoquankhu1.vn
Institution Moves: Can SciSparc Ltd outperform in the next rallyEntry Point & Community Verified Swing Trade Signals - baoquankhu1.vn
Market Trends: What makes SciSparc Ltd stock attractive todayOptions Play & Safe Entry Point Alerts - baoquankhu1.vn
MACD Signal: Is SciSparc Ltd impacted by rising ratesWeekly Risk Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Institution Moves: Is SciSparc Ltd impacted by rising rates2026 Drop Watch & Breakout Confirmation Alerts - baoquankhu1.vn
Buyback Watch: Can SciSparc Ltd outperform in the next rallyWeekly Trade Analysis & Smart Allocation Stock Tips - baoquankhu1.vn
SPRC Should I Buy - Intellectia AI
SPRC Stock Analysis: SciSparc Ltd. Ordinary Shares biotech 0.41% dip at 3.66 view - Newser
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Whale Trades: How correlated is SciSparc Ltd to the S P5002026 Macro Impact & Entry Point Confirmation Alerts - baoquankhu1.vn
SciSparc (SPRC) director Dayan Alon reports 3,651-share ownership stake - Stock Titan
SPRC SEC FilingsScisparc 10-K, 10-Q, 8-K Forms - Stock Titan
SciSparc (SPRC) director discloses shares, options and RSU awards - stocktitan.net
SciSparc (SPRC) director reports initial share and option holdings - Stock Titan
SciSparc (SPRC) director Revach Moshe discloses initial share and RSU holdings - Stock Titan
SciSparc (SPRC) CEO Adler Oz details share, option and RSU holdings - Stock Titan
SciSparc (SPRC) director Weiss Amitay details equity holdings - Stock Titan
SciSparc (SPRC) director Vider Lior details shares, options and RSUs - Stock Titan
SciSparc (SPRC) CTO details 5,528 Ordinary Shares and option holdings on Form 3 - Stock Titan
SciSparc (SPRC) director reports 3,651-share stake and RSU grants - Stock Titan
Sentiment Watch: Can SciSparc Ltd stock outperform in a bear marketRecession Risk & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Buyout Rumor: Is SciSparc Ltd impacted by rising ratesMarket Performance Report & Low Drawdown Investment Ideas - baoquankhu1.vn
SciSparc subsidiary files patent for depression treatment By Investing.com - Investing.com India
[SCHEDULE 13G] SciSparc Ltd. Passive Investment Disclosure (>5%) - Stock Titan
SciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent Filing - TipRanks
Eli Zamir reports ≤5% stake in SciSparc (NASDAQ: SPRC) - Stock Titan
SciSparc (NASDAQ: SPRC) collaboration advances MEAI-PEA depression patent bid - Stock Titan
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Bitget
SciSparc subsidiary files patent for depression treatment - Investing.com
SciSparc Ltd. Reports NeuroThera Labs' Patent Application for Innovative Depression Treatment Combining MEAI and PEA - quiverquant.com
SciSparc Subsidiary NeuroThera to Take Majority Stake in Quantum Trials Firm CliniQuantum - TipRanks
SciSparc (Nasdaq: SPRC) unit to acquire 54% of CliniQuantum and lose NeuroThera control - Stock Titan
SciSparc’s Neurothera Labs announces publication of international patent - TipRanks
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):